Seattle Genetics

Pfizer in Talks to Take Cancer Biotech Seagen

Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in the Wall Street Journal that cited people familiar with the matter. The purchase price could potentially be more than $30 billion.

Surge in Biotech Deals to Unlock Big Investor Profits